Cargando…

Patients’ compliance with different administration routes for allergen immunotherapy in Germany

BACKGROUND: Allergen immunotherapy (AIT) is the practice of administering gradually increasing quantities of an allergen extract to an allergic subject to ameliorate the symptoms associated with the subsequent exposure to the causative allergen. It is the only treatment that may alter the natural co...

Descripción completa

Detalles Bibliográficos
Autores principales: Egert-Schmidt, Anne-Marie, Kolbe, Jan-Marcel, Mussler, Sabine, Thum-Oltmer, Susanne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4216042/
https://www.ncbi.nlm.nih.gov/pubmed/25368517
http://dx.doi.org/10.2147/PPA.S70326
_version_ 1782342200141545472
author Egert-Schmidt, Anne-Marie
Kolbe, Jan-Marcel
Mussler, Sabine
Thum-Oltmer, Susanne
author_facet Egert-Schmidt, Anne-Marie
Kolbe, Jan-Marcel
Mussler, Sabine
Thum-Oltmer, Susanne
author_sort Egert-Schmidt, Anne-Marie
collection PubMed
description BACKGROUND: Allergen immunotherapy (AIT) is the practice of administering gradually increasing quantities of an allergen extract to an allergic subject to ameliorate the symptoms associated with the subsequent exposure to the causative allergen. It is the only treatment that may alter the natural course of allergic diseases. According to AIT guidelines and summary of product characteristics (SmPCs), the treatment should be carried out for at least 3 years. It is controversially discussed whether subcutaneous or sublingual administration routes cause higher patients’ compliance. METHODS: German sales data for different preparations of the allergen manufacturer Allergopharma GmbH & Co. KG were retrospectively evaluated for 5 consecutive years, based on prescriptions per patient: pollen sublingual immunotherapy (SLIT) and high-dose hypoallergenic (allergoid) or unmodified depot pollen and mite preparations for subcutaneous immunotherapy (SCIT). To identify patients’ compliance, “completed treatment years” were determined. A completed treatment year was defined by the required number of prescribed allergen preparations according to the recommended dosage scheme given in the respective SmPCs. RESULTS: Prescription data of 85,241 patients receiving pollen or mite SCIT and 706 patients receiving pollen SLIT were included in this analysis. Patients’ compliance for at least 3 treatment years with high-dose hypoallergenic pollen SCIT was higher when administered perennially (60%) compared to preseasonally (27%). Prescriptions for at least 3 years were received from 42% of patients with pollen SCIT and from 45% of patients with mite SCIT. Compliance with SLIT was lowest with only 16% of patients receiving prescriptions for at least 3 treatment years. Children and adolescents were more compliant than adults, independent of whether they received SLIT or SCIT. CONCLUSION: In general, patients’ compliance with SCIT using high-dose hypoallergenic or unmodified depot preparations was higher than with pollen SLIT. Perennial application of SCIT seems to increase compliance in comparison to the preseasonal application. Children and adolescents were most compliant, independent of the preparation applied.
format Online
Article
Text
id pubmed-4216042
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-42160422014-11-03 Patients’ compliance with different administration routes for allergen immunotherapy in Germany Egert-Schmidt, Anne-Marie Kolbe, Jan-Marcel Mussler, Sabine Thum-Oltmer, Susanne Patient Prefer Adherence Original Research BACKGROUND: Allergen immunotherapy (AIT) is the practice of administering gradually increasing quantities of an allergen extract to an allergic subject to ameliorate the symptoms associated with the subsequent exposure to the causative allergen. It is the only treatment that may alter the natural course of allergic diseases. According to AIT guidelines and summary of product characteristics (SmPCs), the treatment should be carried out for at least 3 years. It is controversially discussed whether subcutaneous or sublingual administration routes cause higher patients’ compliance. METHODS: German sales data for different preparations of the allergen manufacturer Allergopharma GmbH & Co. KG were retrospectively evaluated for 5 consecutive years, based on prescriptions per patient: pollen sublingual immunotherapy (SLIT) and high-dose hypoallergenic (allergoid) or unmodified depot pollen and mite preparations for subcutaneous immunotherapy (SCIT). To identify patients’ compliance, “completed treatment years” were determined. A completed treatment year was defined by the required number of prescribed allergen preparations according to the recommended dosage scheme given in the respective SmPCs. RESULTS: Prescription data of 85,241 patients receiving pollen or mite SCIT and 706 patients receiving pollen SLIT were included in this analysis. Patients’ compliance for at least 3 treatment years with high-dose hypoallergenic pollen SCIT was higher when administered perennially (60%) compared to preseasonally (27%). Prescriptions for at least 3 years were received from 42% of patients with pollen SCIT and from 45% of patients with mite SCIT. Compliance with SLIT was lowest with only 16% of patients receiving prescriptions for at least 3 treatment years. Children and adolescents were more compliant than adults, independent of whether they received SLIT or SCIT. CONCLUSION: In general, patients’ compliance with SCIT using high-dose hypoallergenic or unmodified depot preparations was higher than with pollen SLIT. Perennial application of SCIT seems to increase compliance in comparison to the preseasonal application. Children and adolescents were most compliant, independent of the preparation applied. Dove Medical Press 2014-10-24 /pmc/articles/PMC4216042/ /pubmed/25368517 http://dx.doi.org/10.2147/PPA.S70326 Text en © 2014 Egert-Schmidt et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Egert-Schmidt, Anne-Marie
Kolbe, Jan-Marcel
Mussler, Sabine
Thum-Oltmer, Susanne
Patients’ compliance with different administration routes for allergen immunotherapy in Germany
title Patients’ compliance with different administration routes for allergen immunotherapy in Germany
title_full Patients’ compliance with different administration routes for allergen immunotherapy in Germany
title_fullStr Patients’ compliance with different administration routes for allergen immunotherapy in Germany
title_full_unstemmed Patients’ compliance with different administration routes for allergen immunotherapy in Germany
title_short Patients’ compliance with different administration routes for allergen immunotherapy in Germany
title_sort patients’ compliance with different administration routes for allergen immunotherapy in germany
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4216042/
https://www.ncbi.nlm.nih.gov/pubmed/25368517
http://dx.doi.org/10.2147/PPA.S70326
work_keys_str_mv AT egertschmidtannemarie patientscompliancewithdifferentadministrationroutesforallergenimmunotherapyingermany
AT kolbejanmarcel patientscompliancewithdifferentadministrationroutesforallergenimmunotherapyingermany
AT musslersabine patientscompliancewithdifferentadministrationroutesforallergenimmunotherapyingermany
AT thumoltmersusanne patientscompliancewithdifferentadministrationroutesforallergenimmunotherapyingermany